RGEN vs RGNX

Repligen Corporation vs REGENXBIO Inc. — Valuation Comparison 2026

RGEN

Biological Products, (No Diagnostic Substances)
Repligen Corporation
Quality
7.5
out of 10
Value Trap
23
SAFE
Price
$123.95
Last close
Models
13/13
Active
VS

RGNX

Biological Products, (No Diagnostic Substances)
REGENXBIO Inc.
Quality
6.4
out of 10
Value Trap
18
SAFE
Price
$7.01
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType RGEN Fair ValueRGEN Upside RGNX Fair ValueRGNX Upside
Bayesian DCF Intrinsic $41.23 -66.7% $0.69 -90.1%
Earnings Power Value Intrinsic $10.32 -91.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $8.20 -93.4% $1.93 -72.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RGEN vs RGNX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RGEN vs RGNX — Which Stock Is More Undervalued?

RGEN scores higher with a 7.5/10 quality rating vs RGNX's 6.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Repligen Corporation (RGEN) and REGENXBIO Inc. (RGNX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RGEN currently trades at $123.95 with a QOC of 7.5/10, while RGNX trades at $7.01 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).